AILBRY - Article Search
Serach over 250 million academic articles from all areas of study
Results for 'Alshad S. Lalani'
:
HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody <i>in vivo</i>
Publication Year: 2017
DOI: https://doi.org/10.18632/oncotarget.21660
Abstract:
Add to Library
Authors:
Laurence Booth
Jane L. Roberts
Andrew Poklepovic
Francesca Avogadri-Connors
Richard E. Cutler
Alshad S. Lalani
Paul Dent
Abstract CT001: Neratinib in <i>HER2</i> or <i>HER3</i> mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study
Publication Year: 2017
DOI: https://doi.org/10.1158/1538-7445.am2017-ct001
Abstract:
Add to Library
Authors:
David M. Hyman
Sarina A. Piha‐Paul
Jordi Rodón
Cristina Saura
Geoffrey I. Shapiro
David I. Quinn
Víctor Moreno
Ingrid A. Mayer
Carlos L. Arteaga
Valentina Boni
Emiliano Calvo
Sherene Loi
A. Craig Lockhart
Lillian M. Smyth
Joseph P. Erinjeri
Maurizio Scaltriti
Gary A. Ulaner
Jean Torrisi
Juber Patel
Jiabin Tang
Fanli Meng
Duygu Selcuklu
Helen Won
Nancy Bouvier
Michael F. Berger
Richard E. Cutler
Feng Xu
Anna Butturini
Lisa D. Eli
Grace Mann
Alshad S. Lalani
Richard Bryce
Funda Meric‐Bernstam
José Baselga
David B. Solit
Abstract LB-103: Landscape of somatic ERBB2 Mutations: Findings from AACR GENIE and comparison to ongoing ERBB2 mutant basket study
Publication Year: 2017
DOI: https://doi.org/10.1158/1538-7445.am2017-lb-103
Abstract:
Add to Library
Authors:
Alison M. Schram
Helen Won
Fabrice André
Mónica Arnedos
F. Meric Bernstam
Philippe L. Bédard
Kenna Shaw
Hugo M. Horlings
Christine Micheel
Ben Ho Park
Grace Mann
Alshad S. Lalani
Lillian M. Smyth
David B. Solit
Deborah Schrag
Mia Levy
Barrett J. Rollins
Mark J. Routbort
Charles L. Sawyers
Eva M. Lepisto
Michael F. Berger
David M. Hyman
Abstract 4818: Neratinib/fulvestrant but not fulvestrant alone maintain complete responses after treatment with trastuzumab/paclitaxel of mice bearing ER+/HER2+ xenografts
Publication Year: 2017
DOI: https://doi.org/10.1158/1538-7445.am2017-4818
Abstract:
Add to Library
Authors:
Luis J. Schwarz
Sarah Croessmann
Francesca Avogadri-Connors
Richard E. Cutler
Alshad S. Lalani
Carlos L. Arteaga
Abstract PS4-13: Irreversible inhibition of HER2 activating mutations with neratinib enhances the pre-clinical efficacy of trastuzumab emtansine and trastuzumab deruxtecan
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-ps4-13
Abstract:
Add to Library
Authors:
Ron Bose
Shunqiang Li
Tina Primeau
Maureen Highkin
Ashley R. Tipton
Nagalaxmi Vemalapally
Xuefeng Gao
Gail Sudlow
Irmina Diala
Tao Yu
Jingqin Luo
Ian S. Hagemann
Chieh‐Yu Lin
Richard Bryce
Alshad S. Lalani
Samuel Achilefu
X. Cynthia
Abstract 4038: Exploring optimal targeted combination therapies with neratinib for HER2+ breast cancer
Publication Year: 2017
DOI: https://doi.org/10.1158/1538-7445.am2017-4038
Abstract:
Add to Library
Authors:
Ming Zhao
Stephen Scott
Kurt W. Evans
Erkan Yuca
Rashmi K. Murthy
Francesca Avogadri-Connors
Richard E. Cutler
Alshad S. Lalani
Sarina A. Piha‐Paul
Funda Meric‐Bernstam
Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT ‘basket’ trial
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.sabcs19-p1-19-08
Abstract:
Add to Library
Authors:
Hans Wildiers
Valentina Boni
Cristina Saura
Mafalda Oliveira
Komal Jhaveri
Helen Won
François‐Clément Bidard
Adam Brufsky
Mark E. Burkard
Andrés Cervantes
Carlos Fernández-Martos
Barbara Haley
Sherene Loi
Iben Spanggaard
Stefano Panni
Janice Lu
Melanie Dujka
Feng Xu
Sonia Maciá
Lisa D. Eli
Alshad S. Lalani
Sarina A. Piha‐Paul
Funda Meric‐Bernstam
David B. Solit
David M. Hyman
Abstract PD1-05: Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant for <i>HER2</i>-mutant, hormone receptor-positive, metastatic breast cancer
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-pd1-05
Abstract:
Add to Library
Authors:
Komal Jhaveri
Cristina Saura
Ángel Guerrero-Zotano
Iben Spanggaard
François‐Clément Bidard
Jonathan W. Goldman
José Á. García-Sáenz
Andrés Cervantes
Valentina Boni
John Crown
Adam Brufsky
Sherene Loi
Barbara Haley
Ingrid A. Mayer
Stephen Chia
Janice Lu
James Waisman
Noa Ben-Baruch
Mark E. Burkard
Jennifer M. Suga
Lucía González‐Cortijo
Bruno Perrucci
Feng Xu
Sofia Wong
Jie Zhang
Lisa D. Eli
Alshad S. Lalani
Hans Wildiers
Abstract 1923: KRAS-mutant (mt) colorectal cancer (CRC) organoid models generated from patient-derived xenografts (PDX) show response to combination of trametinib (Tm), neratinib (N), and trastuzumab (Tz)
Publication Year: 2019
DOI: https://doi.org/10.1158/1538-7445.am2019-1923
Abstract:
Add to Library
Authors:
Rekha Pal
Ashok Srinivasan
Peter C. Lucas
Carmen J. Allegra
Angela M. Davies
Alshad S. Lalani
Samuel A. Jacobs
Katherine L. Pogue‐Geile
Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.am2021-ct026
Abstract:
Add to Library
Authors:
X. Cynthia
Jingqin Luo
Rachel A. Freedman
Timothy Pluard
Julie R. Nangia
Janice Lu
Frances Valdez-Albini
Melody A. Cobleigh
Jason M. Jones
Nancy U. Lin
Eric P. Winer
P. Kelly Marcom
Shana Thomas
J. L. Anderson
Brittney Haas
Kimberly M. Hamann
Richard Bryce
Alshad S. Lalani
Lisa A. Carey
Matthew P. Goetz
Feng Gao
Gretchen Kimmick
Mark D. Pegram
Matthew J. Ellis
Ron Bose
Abstract 1077: Acquired neratinib resistance is associated with acquisition of <i>HER2</i> and <i>PIK3CA</i> mutations and can be overcome using potent drug combinations in HER2-positive breast cancer models
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.am2021-1077
Abstract:
Add to Library
Authors:
Jamunarani Veeraraghavan
Ragini M. Mistry
Sarmistha Nanda
Sreyashree Bose
Chia Chia Liu
Vidyalakshmi Sethunath
Martin J. Shea
Tamika Mitchell
Meenakshi Anurag
Michael A. Mancini
Irmina Diala
Alshad S. Lalani
Fabio Stossi
C. Kent Osborne
Mothaffar F. Rimawi
Rachel Schiff
Abstract 4527: Patient-derived organoids and xenografts identify neratinib plus HER2 antibody drug conjugate as a synergistic drug combination for HER2 mutated, nonamplified metastatic breast cancer
Publication Year: 2019
DOI: https://doi.org/10.1158/1538-7445.am2019-4527
Abstract:
Add to Library
Authors:
Shunqiang Li
Highkin Maureen
Tina Primeau
Stephanie L. Pratt
Irmina Diala
Richard E. Cutler
Grace Mann
Alshad S. Lalani
X. Cynthia
Ron Bose
Abstract 1828: Hyperactivation of mTORC1 drives acquired resistance to the pan HER tyrosine kinase inhibitor neratinib in HER2 mutant cancers
Publication Year: 2018
DOI: https://doi.org/10.1158/1538-7445.am2018-1828
Abstract:
Add to Library
Authors:
Dhivya R. Sudhan
Ariella B. Hanker
Ángel Guerrero-Zotano
Luigi Formisano
Yan Guo
Qi Liu
Francesca Avogadri-Connors
Richard E. Cutler
Alshad S. Lalani
Richard Bryce
Alan Auerbach
Carlos L. Arteaga
Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial
Publication Year: 2019
DOI: https://doi.org/10.1158/1538-7445.am2019-929
Abstract:
Add to Library
Authors:
Helen Won
S. Duygu Selçuklu
Sarina A. Piha‐Paul
Cristina Saura
Jordi Rodón
Ingrid A. Mayer
Sherene Loi
Geoffrey I. Shapiro
Janice Lu
Adam Brufsky
Catherine Zimel
Myra Melcer
Maurizio Scaltriti
Lisa D. Eli
Richard E. Cutler
Alshad S. Lalani
Richard Bryce
Carlos L. Arteaga
Funda Meric‐Bernstam
Michael F. Berger
David B. Solit
Alison M. Schram
David M. Hyman
Abstract GS6-04: Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.sabcs19-gs6-04
Abstract:
Add to Library
Authors:
Ariella B. Hanker
Harikrishna Sekar Jayanthan
Dan Ye
Chang‐Ching Lin
Hiroaki Akamatsu
Jonathan H. Sheehan
James P. Koch
Dhivya R. Sudhan
Monica Red Brewer
Alberto Servetto
Jie He
Vincent A. Miller
Alshad S. Lalani
Jens Meiler
Carlos L. Arteaga
Found 46 results in 0.073 seconds
What is Boolean Searches
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE . You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Example Search
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"